Keratoconus (KC) is a progressive, noninflammatory, bilateral (but usually asymmetrical) ectatic corneal disease, characterized by paraxial stromal thinning and weakening that leads to corneal surface distortion.
Visual loss occurs primarily from irregular astigmatism and myopia, and secondarily from corneal
Typically commences at puberty and progresses to the mid-thirties at which time progression slows
and often stops.
Between age 12 and 35, it can arrest or progress at any time and there is no way to predict how fast
it will progress or if it will progress at all.
In general young patients with advanced disease are more likely to progress to the point where they
may ultimately require some form of surgical intervention. Management.
Subclinical Keratoconus(KC) normally causes no visual impairment, the patient may require glasses
or nothing to achieve 20/20 vision.
Clinical Keratoconus is classified in several stages according to the conus severity.
The initial stages can be anticipated with contact lenses while the more advanced stages may need implantation of intracorneal rings, or laser combined with corneal cross-linking.
The final stage can be treated only with Keratoplasty(corneal transplantation).
A non-invasive treatment CXL (corneal collagen cross-linking riboflavin) treatment has been proven to strengthen the weak corneal structure in Keratoconus.This method works by increasing collagen cross-linking, which are the natural "anchors" within the cornea.These anchors are responsible for preventing the cornea from bulging out and becoming steep and irregular (which is the cause of Keratoconus).During the 30-minute, in-office treatment, custom-made riboflavin eyedrops are applied to the cornea, which are then activated by a special light. This is the process that has been shown in laboratory and clinical studies to increase the amount of collagen cross-linking in the cornea and strengthen the cornea.In published studies, such treatments were proven safe and effective in patients.